AUTL
Autolus TherapeuticsAUTL
AUTL
About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Employees: 647
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
0.13% less ownership
Funds ownership: 63.26% [Q4 2024] → 63.13% (-0.13%) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
14% less funds holding
Funds holding: 108 [Q4 2024] → 93 (-15) [Q1 2025]
34% less capital invested
Capital invested by funds: $395M [Q4 2024] → $261M (-$134M) [Q1 2025]
40% less call options, than puts
Call options by funds: $87K | Put options by funds: $145K
65% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 23
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
183%
upside
Avg. target
$8.67
309%
upside
High target
$10
372%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum | 372%upside $10 | Buy Reiterated | 12 Jun 2025 |
Truist Securities Asthika Goonewardene | 372%upside $10 | Buy Maintained | 1 Apr 2025 |
Wells Fargo Yanan Zhu | 183%upside $6 | Overweight Maintained | 21 Mar 2025 |
Financial journalist opinion
Based on 5 articles about AUTL published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces updated long term data (up to approximately three years of follow up) from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), to be presented in an oral presentation at the European Hematology Association (EHA) Congress between June 12-15, 2025, in Milan, Italy. Autolus will also present an additional oral and poster presentation, the details of which are included below.
Positive
Seeking Alpha
1 week ago
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Autolus Therapeutics plc is a UK-based biotech that has brought its ex-vivo CAR-T cell therapy to market in B-ALL with a "best-in-class" safety/efficacy profile. In this small indication, peak revenues may be no more than $200 - $300m, but the drug's launch has been successful, with $9m earned in Q1 2025. Autolus plans to share more data from its FELIX study imminently, which could open up approval shots in other liquid cancer indications.
Neutral
GlobeNewsWire
2 weeks ago
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences. William Blair 45 th Annual Growth Stock Conference Management to host investor meetingsDate: June 3, 2025Location: Chicago, IL Jefferies Global Healthcare Conference Fireside Chat PresentationDate and time: June 5, 2025; 3:10pm EDT / 20:10pm BSTLocation: New York, NYPresenter: Chief Executive Officer Dr. Christian Itin Goldman Sachs 46 th Annual Global Healthcare Conference Fireside Chat PresentationDate and time: June 11, 2025; 1:20pm EDT / 18:20 BSTLocation: Miami, FLPresenter: Chief Financial Officer Rob Dolski A webcast of the fireside chats will be available on the “Events” page in the “Investor Relations & Media” section of the Company's website at https://www.autolus.com/investor-relations-media/events/.
Neutral
GlobeNewsWire
3 weeks ago
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-ALL
Positive
Seeking Alpha
3 weeks ago
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
GlobeNewsWire
1 month ago
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).
Neutral
Seeking Alpha
1 month ago
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Amanda Cray – Executive Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants James Shin – Deutsche Bank Matthew Phipps – William Blair Karina Rabayeva – Truist Gil Blum – Needham & Company Yanan Zhu – Wells Fargo Operator Good day, and thank you for standing by. Welcome to the Autolus First Quarter 2025 Financial Results Conference Call.
Neutral
GlobeNewsWire
1 month ago
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 million U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025 Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON, May 08, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the first quarter ended March 31, 2025. “We had a great first quarter of launch and are highly encouraged by physician enthusiasm for AUCATZYL in the U.S. We believe this speaks to the product profile and significant unmet need for patients,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Neutral
GlobeNewsWire
1 month ago
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory
Neutral
GlobeNewsWire
1 month ago
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS) Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025 Company plans to advance obe-cel in progressive forms of multiple sclerosis (MS); first patient expected to be dosed in Phase 1 trial by year-end 2025 LONDON, April 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event. The Company presented development plans to expand the obe-cel opportunity into autoimmune disease, including a potential registrational path for obe-cel in LN.
Charts implemented using Lightweight Charts™